Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

Kambiz Rahbar; Markus Essler; Kim M Pabst; Matthias Eiber; Christian Peter la Fougère; Vikas Prasad; Philipp Rassek; Ergela Hasa; Helmut Dittmann; Ralph A Bundschuh; Wolfgang Peter Fendler; Milena Kurtinecz; Anja Schmall; Frank Verholen; Alton O Sartor

doi:10.2967/jnumed.122.264456

OtherBrief Communication

Open Access

Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

Kambiz Rahbar, Markus Essler, Kim M Pabst, Matthias Eiber, Christian Peter la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A Bundschuh, Wolfgang Peter Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen and Alton O Sartor

Journal of Nuclear Medicine October 2022, jnumed.122.264456; DOI: https://doi.org/10.2967/jnumed.122.264456

Kambiz Rahbar

1 University of Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Markus Essler

2 University Hospital Bonn, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim M Pabst

3 University Hospital Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

4 Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian Peter la Fougère

5 University Hospital Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Christian Peter la Fougère

Vikas Prasad

6 University of Ulm, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Vikas Prasad

Philipp Rassek

1 University of Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ergela Hasa

4 Technical University of Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Helmut Dittmann

7 University of Tübingen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ralph A Bundschuh

8 University Augsburg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang Peter Fendler

3 University Hospital Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Wolfgang Peter Fendler

Milena Kurtinecz

9 Bayer HealthCare Pharmaceuticals, United States;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anja Schmall

10 Bayer Consumer Care, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank Verholen

10 Bayer Consumer Care, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alton O Sartor

11 Tulane University School of Medicine, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Article Figures & Data

Additional Files

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 6

June 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

Journal of Nuclear Medicine Oct 2022, jnumed.122.264456; DOI: 10.2967/jnumed.122.264456

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Journal of Nuclear Medicine Oct 2022, jnumed.122.264456; DOI: 10.2967/jnumed.122.264456

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

Google Scholar

Brief Communication

Measuring Total Metabolic Tumor Volume from ¹⁸F-FDG PET: A Reality Check
Bioanalytic Hybrid System Merging 3-Dimensional Cell Culture and Chromatographic Precision for Unprecedented Preclinical Insights in Molecular Imaging
Radiances of Cerenkov-Emitting Radionuclides on the In Vivo Imaging System

Show more Brief Communication

Clinical (Oncology: GU)

Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
A Comparison of ¹⁸F-DCFPyL, ¹⁸F-NaF, and ¹⁸F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
Detection of Additional Primary Neoplasms on ¹⁸F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer

Show more Clinical (Oncology: GU)

Keywords

Bone
Oncology: GU
radionuclide therapy
Lutetium-177-PSMA
metastatic castration-resistant prostate cancer
Radium-223
real-world practice
targeted alpha therapy

Main menu

User menu

Search

Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

Article Figures & Data

Additional Files

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Brief Communication

Clinical (Oncology: GU)

Similar Articles

Keywords